Clinical Trial Update: Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B [Phase 4]

View source ↗

Summary

A Phase 4 trial to evaluate entecavir with or without pegylated interferon alpha-2b in children aged 3-6 with immune-tolerant chronic hepatitis B; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ENTECAVIR (ENTECAVIR)
• Pegylated Interferon α-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: Qing-Lei Zeng | Conditions: Hepatitis B Virus Infection, Children | Phase 4 | Status: NOT_YET_RECRUITING